JUNSHI BIO (01877): Tislelizumab approved for marketing by the UK Medicines and Healthcare products Regulatory Agency

JUNSHI BIO (01877) announces that its wholly-owned subsidiary, TopAlliance Biosciences Inc., has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory Agency for the product teprotumumab (trade name: LOQTORZI). This approval allows for the treatment of two indications: teprotumumab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, unresectable or metastatic nasopharyngeal cancer who cannot undergo surgery or radiotherapy, and teprotumumab in combination with cisplatin and paclitaxel for the first-line treatment of unresectable, recurrent or metastatic esophageal squamous cell carcinoma in adults. Teprotumumab is the first and only drug approved in the UK for the treatment of nasopharyngeal cancer and the only first-line treatment option for unresectable or metastatic esophageal squamous cell carcinoma with no restriction on PD-L1 expression in the UK.